Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICSI
NCT03111810Phase 2Completed
- Sponsor
- University of Oxford
- Start
- May 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD4017 in iatrogenic Cushing's syndrome (iCS) (2 arms), sponsored by University of Oxford. Primary endpoint: Changes in the detrimental side effects of prednisolone by AZD4017 at 2 years. Started May 2017; status: completed.
02
Drugs
AZD4017
03
Conditions
iatrogenic Cushing's syndrome (iCS)
Beyond the preview
Go deeper on NCT03111810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111810.